Literature DB >> 15801839

CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists.

Frank Boeckler1, Ursula Ohnmacht, Thomas Lehmann, Wolfgang Utz, Harald Hübner, Peter Gmeiner.   

Abstract

As an extension of a series of dopamine D(3) receptor agonists involving FAUC 54, ex-chiral pool synthesis, and biological evaluation of 3-substituted 7-aminotetrahydroindolizines was performed. Considering the structural features of both series of enantiomers, we developed a novel alignment hypothesis for D(3) agonists, allowing for the placement of the aromatic moieties on two alternative, adjacent positions. CoMFA and CoMSIA analyses yielded significant cross-validated q(2) values of 0.726 and 0.590, respectively, when a newly invented program application (IRAS) controlling the alignment selection proved to be useful. Employing the CoMFA/CoMSIA contribution maps, we were able to transform a previously constructed homology model of the D(3) receptor from an inactive into an activate state. Besides the established ionic interactions, we propose pi-stacking with Phe6.51 and a hydrogen bond between His6.55 and the acyl moiety to be primarily involved in the D(3) receptor binding of FAUC 54 and its analogues.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801839     DOI: 10.1021/jm049269+

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Selectivity and activation of dopamine D3R from molecular dynamics.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Mol Model       Date:  2012-07-03       Impact factor: 1.810

Review 2.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

3.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 4.  Beyond small-molecule SAR: using the dopamine D3 receptor crystal structure to guide drug design.

Authors:  Thomas M Keck; Caitlin Burzynski; Lei Shi; Amy Hauck Newman
Journal:  Adv Pharmacol       Date:  2014

5.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.

Authors:  Frank M Boeckler; Andreas C Joerger; Gaurav Jaggi; Trevor J Rutherford; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

6.  Understanding the Structural Requirements of Hybrid (S)-6-((2-(4-Phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its Analogs as D2/D3 Receptor Ligands: A Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Investigation.

Authors:  Gyan Modi; Horrick Sharma; Prashant S Kharkar; Aloke K Dutta
Journal:  Medchemcomm       Date:  2014-09-01       Impact factor: 3.597

7.  Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.

Authors:  Hongbo Liu; Xia Wang; Jian Wang; Jinghui Wang; Yan Li; Ling Yang; Guohui Li
Journal:  Int J Mol Sci       Date:  2011-10-20       Impact factor: 5.923

8.  Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.

Authors:  Gyan Modi; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  J Med Chem       Date:  2014-02-12       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.